Abstract
The advent of cisplatin was a breakthrough in the chemotherapy of certain cancers. Its success, in spite of adverse effects such as nephrotoxicity, nausea and vomiting, ototoxicity and myelosuppression, attests to its efficacy1. Still, the cost of treatment, in terms of patient quality of life, underscores the need for an efficacious drug with milder side effects. Carboplatin is an example of an agent specifically developed to reduce side effects while retaining the antitumor activity of cisplatin2. Its tremendous success, following its introduction in Europe and the US, attests to the importance of addressing patient quality of life. Although, oral chemotherapeutic agents are not presently a significant factor in cancer treatment, a properly designed agent could offer significant advantages in terms of a patients’ comfort and convenience, and anticipates the possibility of outpatient chemotherapy. At Johnson Matthey, in conjunction with the Institute of Cancer Research and Bristol-Myers Squibb, a portion of our platinum antitumor drug discovery program is devoted to the design and development of an orally active platinum antitumor drug. This paper describes the synthesis, reactions, and a few of the biological properties of a new class of antitumor agents that possess many characteristics required of an orally active antitumor agent.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wiltshaw, E, presented at symposium Carboplatin: Current Status and Future Prospects. Stockholm, June 19, 1985.
Foster, B.J.; Harding, B. J.; Wolpert-DeFilippes, M.K.; Rubinstein, L.Y.; Clagett-Carr, K.; Leyland-Jones B. Canc. Chemo. Pharm. 1990,25, 395–404.
Kararli, T.T. in Critical Reviews in Therapeutic Drug Carrier Systems 1989, 6, 39–86.
Sherman, S.E.; Gibson, D.; Wang, A.H.J.; Lippard, S.J. Science, 1985, 230, 412–17.
Morgan, S.E.,; Boxall F.E.; Murrer, B.A.; Giandomenico C. M.; Wyer S.B.; Harrap, K.R. Sixth Intl. Symp. on Platinum and other Metal Coord. Compds., 1991, 229.
Prof. Jon Zubieta, Syracuse University, private communication.
Cowens, J.W.; Steive, F.A.; Alderfer, J.L; Hansen, G.E.; Pendyala, L.; Creaven, P.J. Int. J. Mass. Spect. Ion Phys. 1983,48, 177–80.
Stephen G. Chancey, Steven Wyrick, Gail Kaun Till, Cancer Research, 1990, 50, 4539–4.
Blatter, E.E., Vollano, J.F.; Krishna, B.S.; Dabrowiak, J.C. Biochemistry, 1984, 23, 4817.
Evans, J.E.; Green, M.; Inorg. Chim. Acta, 1987, 183-4.
Burchenal, J.H. et al Recent Results in Cancer Res. 1980, 74, 146.
Kelland, L.R.; Abel, G.; Harrap, K.R. Proc. A.A.C.R., 1989, 609.
Binks, S.P; Dobrota, M. Biochemical Soc. Trans., 1986, 14, 694–5.
Morgan, S.E.; Webster, L.K.; Boxall, F.E.; Siddik, Z.H.; Murrer, B.A.; Harrap K.R. presented in Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989.
Goddard, P.M., Valenti, M.R., Murrer, B.A., Harrap K.R., presented in Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989.
Harrap, K.R. Cancer Treat. Rev., 1985, 21-33.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Giandomenico, C.M. et al. (1991). Synthesis and Reactions of a New Class of Orally Active Pt(IV) Antitumor Complexes. In: Howell, S.B. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0738-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0738-7_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0740-0
Online ISBN: 978-1-4899-0738-7
eBook Packages: Springer Book Archive